Boston Scientific Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy BSX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 63.420
Low
94.00
Averages
108.14
High
132.00
Current: 63.420
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
Cash-Rich Companies: Strong Flow but Investment Risks
- SunOpta's Declining Performance: SunOpta (NASDAQ:STKL) has seen a 1.6% annual decline in sales over the past three years, and despite a free cash flow margin of 4.8%, its revenue base of $792.4 million puts it at a disadvantage, indicating a lack of loyal customers for its products.
- ProFrac's Financial Strain: ProFrac (NASDAQ:ACDC) has a poor free cash flow margin of just 1%, with a gross margin of 32.8% that is below its competitors, limiting its ability to invest in exploration and production, while its EBITDA margin has decreased by 1.6 percentage points over the last five years.
- Boston Scientific's Growth Potential: Boston Scientific (NYSE:BSX) has achieved an average organic revenue growth rate of 16.6% over the past two years, with annual earnings per share growth of 26%, and a free cash flow margin that increased by 7 percentage points over five years, showcasing its strong profitability and investment potential.
- Rising Market Attention: While SunOpta and ProFrac face challenges, Boston Scientific's stock price of $64.08, with a P/E ratio of 18.7, indicates increasing attractiveness in the market, potentially making it a focal point for investors.
See More
Wall Street Optimism Rises Amid Ceasefire Hopes
- Market Rebound: The S&P 500 and Nasdaq Composite reached all-time highs this week, with the S&P 500 surpassing 7,100 for the first time, reflecting strong investor confidence in economic recovery and suggesting further upward momentum for equities.
- Earnings Expectations: According to FactSet, the S&P 500 is projected to have a blended growth rate of 12.5% in Q1, with 78% of reporting companies exceeding expectations, providing a positive backdrop for the upcoming earnings season that could further bolster market confidence.
- Oil Price Volatility: While oil prices have fallen to around $80 per barrel, significantly below the $110 peak during the conflict, the market must remain vigilant regarding the potential impacts of U.S.-Iran tensions on global supply chains, particularly concerning the safety of transit through the Strait of Hormuz.
- Technical Fragility: Despite the market's strong short-term performance, analyst Craig Johnson warns that the rapid transition from oversold to overbought conditions masks underlying macroeconomic risks, urging investors to remain cautious and focus on high-quality investment opportunities.
See More
Boston Scientific Faces Securities Litigation Warning
- Litigation Investigation: Faruqi & Faruqi LLP is investigating potential claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Disappointing Performance: Boston Scientific's February 4, 2026, earnings report revealed that U.S. EP sales fell short of expectations, leading to a significant net income miss and disappointing guidance for fiscal 2026, highlighting a stark contrast between management's optimistic market growth claims and the actual performance.
- Stock Price Plunge: Following the disappointing results, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, which directly impacted investors' financial interests and indicated a loss of market confidence in the company's future outlook.
- Legal Rights Reminder: Faruqi & Faruqi encourages affected investors to reach out for information or to participate in the litigation, ensuring their legal rights are protected, while also reminding potential lead plaintiffs that they can apply for lead plaintiff status through their chosen counsel.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Boston Scientific Class Action Lawsuit Notification
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors needing to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported a fourth-quarter net income of $672 million, or $0.45 per share, which, despite year-over-year growth, fell short of the expected range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, which have eroded its market share and limited growth potential, indicating a threat to the company's position in the industry.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its expertise and successful track record in handling such cases.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
Cash-Rich Companies: Strong Flow but Investment Risks
- SunOpta's Declining Performance: SunOpta (NASDAQ:STKL) has seen a 1.6% annual decline in sales over the past three years, and despite a free cash flow margin of 4.8%, its revenue base of $792.4 million puts it at a disadvantage, indicating a lack of loyal customers for its products.
- ProFrac's Financial Strain: ProFrac (NASDAQ:ACDC) has a poor free cash flow margin of just 1%, with a gross margin of 32.8% that is below its competitors, limiting its ability to invest in exploration and production, while its EBITDA margin has decreased by 1.6 percentage points over the last five years.
- Boston Scientific's Growth Potential: Boston Scientific (NYSE:BSX) has achieved an average organic revenue growth rate of 16.6% over the past two years, with annual earnings per share growth of 26%, and a free cash flow margin that increased by 7 percentage points over five years, showcasing its strong profitability and investment potential.
- Rising Market Attention: While SunOpta and ProFrac face challenges, Boston Scientific's stock price of $64.08, with a P/E ratio of 18.7, indicates increasing attractiveness in the market, potentially making it a focal point for investors.
See More
Wall Street Optimism Rises Amid Ceasefire Hopes
- Market Rebound: The S&P 500 and Nasdaq Composite reached all-time highs this week, with the S&P 500 surpassing 7,100 for the first time, reflecting strong investor confidence in economic recovery and suggesting further upward momentum for equities.
- Earnings Expectations: According to FactSet, the S&P 500 is projected to have a blended growth rate of 12.5% in Q1, with 78% of reporting companies exceeding expectations, providing a positive backdrop for the upcoming earnings season that could further bolster market confidence.
- Oil Price Volatility: While oil prices have fallen to around $80 per barrel, significantly below the $110 peak during the conflict, the market must remain vigilant regarding the potential impacts of U.S.-Iran tensions on global supply chains, particularly concerning the safety of transit through the Strait of Hormuz.
- Technical Fragility: Despite the market's strong short-term performance, analyst Craig Johnson warns that the rapid transition from oversold to overbought conditions masks underlying macroeconomic risks, urging investors to remain cautious and focus on high-quality investment opportunities.
See More
Boston Scientific Faces Securities Litigation Warning
- Litigation Investigation: Faruqi & Faruqi LLP is investigating potential claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Disappointing Performance: Boston Scientific's February 4, 2026, earnings report revealed that U.S. EP sales fell short of expectations, leading to a significant net income miss and disappointing guidance for fiscal 2026, highlighting a stark contrast between management's optimistic market growth claims and the actual performance.
- Stock Price Plunge: Following the disappointing results, Boston Scientific's stock price plummeted by $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, which directly impacted investors' financial interests and indicated a loss of market confidence in the company's future outlook.
- Legal Rights Reminder: Faruqi & Faruqi encourages affected investors to reach out for information or to participate in the litigation, ensuring their legal rights are protected, while also reminding potential lead plaintiffs that they can apply for lead plaintiff status through their chosen counsel.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Boston Scientific Class Action Lawsuit Notification
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors needing to apply as lead plaintiffs by May 4, 2026, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported a fourth-quarter net income of $672 million, or $0.45 per share, which, despite year-over-year growth, fell short of the expected range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, which have eroded its market share and limited growth potential, indicating a threat to the company's position in the industry.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its expertise and successful track record in handling such cases.
See More
